Cargando…

The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C

BACKGROUND: Non-organ-specific autoantibodies are found in a considerable number of anti-HCV positive patients. Previous studies investigated the clinical relevance of these antibodies in patients treated with interferon monotherapy, but not combination therapies. METHODS: Anti-nuclear, anti-smooth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wasmuth, Hermann E, Stolte, Christian, Geier, Andreas, Dietrich, Christoph G, Gartung, Carsten, Lorenzen, Johann, Matern, Siegfried, Lammert, Frank
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC373450/ https://www.ncbi.nlm.nih.gov/pubmed/15040810 http://dx.doi.org/10.1186/1471-2334-4-4

Ejemplares similares

Hyperglycemia at admission to ICU is independently associated with increased serum levels of IL-6 and reduced ex vivo TNF-alpha production
por: Wasmuth, HE, et al.
Publicado: (2003)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Molecular regulation of sinusoidal liver bile acid transporters during cholestasis.
por: Gartung, C., et al.
Publicado: (1997)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

354 Autoimmune Hepatitis Misdiagnosed as Hepatitis C Responding to Interferon/Ribavirine Therapy
por: Pijak, Michal R., et al.
Publicado: (2012)

Presence of HCV RNA in peripheral blood mononuclear cells may predict patients’ response to interferon and ribavirin therapy
por: Zaman, Nasib, et al.
Publicado: (2014)

Longitudinal Study of a Human Drug-Induced Model of Autoantibody to Cytoplasmic Rods/Rings following HCV Therapy with Ribavirin and Interferon-α
por: Keppeke, Gerson Dierley, et al.
Publicado: (2012)

Negative Regulation of Hepatitis C Virus Specific Immunity Is Highly Heterogeneous and Modulated by Pegylated Interferon-Alpha/Ribavirin Therapy
por: Claassen, Mark A. A., et al.
Publicado: (2012)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
por: Danilovic, Debora Lucia Seguro, et al.
Publicado: (2011)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]
por: Veldt, Bart J, et al.
Publicado: (2003)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Serous Retinal Detachments Complicating Interferon-α and Ribavirin Treatment in Patients with Hepatitis C
por: Modorati, Giulio, et al.
Publicado: (2011)

Interferon-Alpha Induced and Ribavirin Induced Thyroid Dysfunction in Patients with Chronic Hepatitis C
por: Nadeem, Amina, et al.
Publicado: (2010)

Hepatitis C virus quasispecies in chronically infected children subjected to interferon–ribavirin therapy
por: Figlerowicz, Magdalena, et al.
Publicado: (2010)

Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
por: Lee, Tae-Hee, et al.
Publicado: (2014)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Case Report: Severe Interstitial Pneumonitis Secondary to Pegylated Interferon α-2b and Ribavirin Treatment of Hepatitis C Infection
por: Fuhrmann, Valentin, et al.
Publicado: (2004)

Autoantibodies to Interferons in Infectious Diseases
por: Quiros-Roldan, Eugenia, et al.
Publicado: (2023)

Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection
por: Kuntzen, Thomas, et al.
Publicado: (2016)

Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C
por: Rathi, Chetan, et al.
Publicado: (2015)

Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin
por: Cuevas, José Manuel, et al.
Publicado: (2008)

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
por: Asselah, Tarik, et al.
Publicado: (2010)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
por: Martins, Elson Vidal, et al.
Publicado: (2009)

Expectoration of Large Bronchial Casts Secondary to the Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin
por: de Araújo, Evaldo Stanislau Affonso, et al.
Publicado: (2010)

Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
por: Alhamlan, Fatimah S, et al.
Publicado: (2014)

Neuro-biological inferences into the depressive disorders of patients with chronic hepatitis C treated with interferon and ribavirin
por: Hurezeanu, Dan, et al.
Publicado: (2014)

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country
por: Hlaing, Naomi Khaing Than, et al.
Publicado: (2016)

Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C
por: Zaily, Dorta Guridi, et al.
Publicado: (2017)

Nonarteritic anterior ischemic optic neuropathy associated with interferon and ribavirin in a patient with hepatitis C
por: Sharif, Walid, et al.
Publicado: (2016)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
por: Rashed, Yasser K., et al.
Publicado: (2020)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_dec7gsl0kco0m17sgnne0hicpq